Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Revenue projections:

Revenue projections for SPARC
Revenue projections for SPARC

SPARC's revenues are expected to rise above the previous year's, which could indicate a strong investment opportunity. If this growth is backed by other key fundamentals, investors may find the company's improving financial performance to be a sign of potential profitability and long-term success.

Financial Ratios:

currentRatio 2.470000
forwardPE 3.995487
debtToEquity 41.776000
earningsGrowth 0.000000
revenueGrowth 67.168000
grossMargins 0.397190
operatingMargins 0.955530
trailingEps 47.870000
forwardEps 55.400000

SPARC's current ratio of 2.47 indicates strong liquidity, meaning the company can comfortably meet its short-term debt obligations. This financial position reflects SPARC's ability to use its cash reserves and current assets to cover liabilities without facing any cash flow issues.
Sun Pharma Advanced Research Company Limited's positive gross and operating margins indicate strong financial performance. These margins show that the company is profitable and efficient in its operations, with effective cost control contributing to its overall financial success.
SPARC's forward EPS is higher than its trailing EPS, which signals that the company is expected to achieve greater profitability this financial year. This suggests improved earnings performance, indicating a positive outlook for SPARC's financial growth.

Price projections:

Price projections for SPARC
Price projections for SPARC



Recommendation changes over time:

Recommendations trend for SPARC
Recommendations trend for SPARC


With analysts showing a buy bias for SPARC, investors may be more inclined to see the stock as an attractive investment. The favorable outlook could spur increased interest, positioning SPARC as a safe and profitable place for investors to allocate their funds and seek growth.